ArticleFrontiers in public health2026
Overview of SARS-CoV-2 genomic surveillance in Central America and the Dominican Republic from February 2020 to January 2023: the impact of PAHO and COMISCA's collaborative efforts.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploratory Insights on Epidemiology, Genomic Features and Pangenome Analysis of NDM-1-Positive Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study provides a comprehensive overview of SARS-CoV-2 genomic surveillance in Central America and the Dominican Republic from February 2020 to January 2023, highlighting the collaborative efforts of the Pan American Health Organization (PAHO), and the Council of Ministers of Health of Central America (COMISCA). A total of 26,595 sequences from the GISAID database were analyzed, correlating findings with key events reported by participating entities. The genomic analysis reveals significant co-circulation of variants, with notable lineage diversity observed throughout the pandemic. Variants of concern (VOC) like Alpha, Gamma, Delta and Omicron were identified alongside variants of interest (VOI) like Lambda and Mu. The emergence of recombinant lineages further illustrates the ongoing evolution of the virus and its spread across the region, underscoring the interconnectedness of Central America and the Dominican Republic. The collaborative model facilitated broader sequencing coverage, enabling more extensive surveillance than individual countries could achieve alone. Despite the successes of regional collaborations, challenges remain, particularly regarding sequencing capacity in countries impacted by socioeconomic inequalities. Addressing these gaps is essential to enhance public health responses to current and future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.